Results 51 to 60 of about 403,583 (300)
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Molecular Oncology, EarlyView.The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués +3 more
wiley +1 more source
Strength through diversity: how cancers thrive when clones cooperate
Molecular Oncology, EarlyView.Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken +3 more
wiley +1 more source
EE84 A Reexamination of Drug Costs for Cetuximab and Panitumimab in Metastatic Colorectal Cancer: Assessing the Influence of Drug Vial Splitting [PDF]
, 2022 S Puskuru +3 more
openalex +1 more source
Next‐generation proteomics improves lung cancer risk prediction
Molecular Oncology, EarlyView.This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj +4 more
wiley +1 more source
OTO OpenObjective Nebulized ciprofloxacin‐dexamethasone (CPD) is an adjuvant, off‐label treatment used to optimize healing after airway surgery, but there is limited data regarding its accessibility.
Abbey L. Landini +5 more
doaj +1 more source
Universal Drug Coverage and Socioeconomic Disparities in Health Care Costs Among Persons With Diabetes [PDF]
, 2020 Wanrudee Isaranuwatchai +8 more
openalex +1 more source
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Orphanet Journal of Rare Diseases, 2019 Background High orphan drug prices have gained the attention of payers and policy makers. These prices may reflect the need to recoup the cost of drug development from a small patient pool.
Kavisha Jayasundara +5 more
doaj +1 more source